Mark E. Webster
Pfizer
8 Papers
11 Citations
Mark E. Webster is an academic researcher from Pfizer. The author has contributed to research in topics: Chemistry & Hydrochloride. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin
Paul Bowles,Steven J. Brenek,Stephane Caron,Nga M. Do,Michele T. Drexler,Shengquan Duan,Pascal Dube,Eric C. Hansen,Brian P. Jones,Kris N. Jones,Tomislav A. Ljubicic,Teresa W. Makowski,Jason Mustakis,Jade D. Nelson,Mark Olivier,Zhihui Peng,Hahdi H. Perfect,David Place,John A. Ragan,John J. Salisbury,Corey L. Stanchina,Brian C. Vanderplas,Mark E. Webster,R. Matt Weekly +23 more
TL;DR: A practical synthesis of SGLT2 inhibitor candidate ertugliflozin has been developed for potential commercial application and high chemical purity of the API is assured through isolation of the crystalline penultimate intermediate, tetraacetate 39.
68
Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib
Christina G. Connor,Jacob C. DeForest,Phil Dietrich,Nga M. Do,Kevin M. Doyle,Shane A. Eisenbeis,Elizabeth Greenberg,Sarah H. Griffin,Brian P. Jones,Kris N. Jones,Michael J. Karmilowicz,Rajesh Kumar,Chad A. Lewis,Emma McInturff,J. Christopher McWilliams,Ruchi Mehta,Bao D. Nguyen,Anil Rane,Brian Samas,Barbara J. Sitter,Howard W. Ward,Mark E. Webster +21 more
TL;DR: The development of a commercial route toward the JAK1 inhibitor abrocitinib is described, and the application of a late-stage Lossen rearrangement provided the desired cis-diaminocyclobutane.
20
Development of the Carbocyclic Nucleoside MDL 201449A: A Tumor Necrosis Factor-α Inhibitor
Timothy Watson,Timothy T. Curran,David A. Hay,Ramnik S. Shah,and David L. Wenstrup,Mark E. Webster +5 more
TL;DR: In this article, an efficient synthesis of (1S,4R)-(−)-4-tert-butyldimethylsilyloxy-2-cyclopentenyl acetate and (1R,4S)-( −)-4t-methyltetylmethylsilylated 2-cyclopentenol is described utilizing a furfuryl alcohol rearrangement, followed by a lithium aluminum hydride reduction.
19
Patent
Methods for preparing SGLT2 inhibitors
Steven J. Brenek,Stephanie Caron,Jade D. Nelson,Mark E. Webster,Rodney Matthew Weekly +4 more
- 10 Mar 2014
TL;DR: In this paper, a method for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT 2 and a (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex was described.
11